Journal Article (Letter)

DZNE-2025-00175

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Gantenerumab in Dominantly Inherited Alzheimer Disease-Reply.

Wagemann, O. (First author)DZNE* ; McDade, E. ; Bateman, R. J.

2025
American Medical Association Chicago, Ill.

This record in other databases:    

Please use a persistent id in citations: doi:10.1001/jamaneurol.2024.3828

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 25 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---

---

Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article Wagemann, O. ; Liu, H. ; Wang, G. ; et al
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
JAMA neurology 81(6), 582 - 593 (2024) [10.1001/jamaneurol.2024.0991]2024   Files BibTeX | EndNote: XML, Text | RIS

---